{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:29:04Z","timestamp":1774430944493,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) represents a distinct, highly aggressive molecular subtype associated with a poor prognosis. While immune checkpoint inhibitors offer potential benefits, therapeutic options remain limited. Notably, SMARCA4 alterations are typically mutually exclusive with classic driver mutations (e.g., EGFR, ALK), rendering targeted therapies generally inapplicable at diagnosis. Consequently, the emergence of actionable driver mutations following systemic therapy is an exceptionally rare but clinically significant phenomenon in this entity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present the case of a 52-year-old male diagnosed with stage T4N3M1a (IVA) SMARCA4-dNSCLC in April 2023, initially presenting with superior vena cava syndrome (SVCS). The patient was managed with a multimodal treatment strategy. Initial thoracic radiotherapy (50 Gy in 25 fractions) successfully alleviated the SVCS, enabling subsequent systemic therapy with tislelizumab, nab-paclitaxel, and carboplatin. Upon first disease progression nine months later (April 2024), he received a second course of radiotherapy (30 Gy in 10 fractions) combined with chemoimmunotherapy, achieving stable disease for five months. Following a second progression in October 2024, which was complicated by recurrent SVCS and malignant effusions, an SVC stent was placed. Critically, dynamic genetic profiling of the pleural effusion in November 2024 identified an emergent EGFR L858R mutation\u2014a finding contrary to the typical mutual exclusivity described in this subgroup and suggests therapy-induced clonal selection. Treatment with a third-generation EGFR-TKI (aumolertinib) was initiated, resulting in significant symptomatic improvement and a progression-free survival of four months. The patient ultimately succumbed to the disease in April 2025, achieving an overall survival (OS) of 24 months. To our knowledge, this is the first report demonstrating the successful sequential integration of radiotherapy and EGFR-TKI therapy in SMARCA4-dNSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our experience demonstrates that a proactive, individualized multimodal strategy\u2014integrating radiotherapy for local control and targeted therapy guided by dynamic molecular profiling\u2014can significantly extend survival beyond the historical median of approximately 12 months for SMARCA4-deficient NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1724204","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:55:37Z","timestamp":1774421737000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: SMARCA4-deficient non-small cell lung cancer \u2014 effective local control with radiotherapy and emergence of a targetable EGFR mutation"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingru","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfa","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuecan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04806-y","article-title":"Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor","volume":"149","author":"Lin","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1038\/s41467-020-19402-8","article-title":"Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients","volume":"11","author":"Fernando","year":"2020","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6083","article-title":"Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer","volume":"12","author":"Liang","year":"2023","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.06.001","article-title":"Recent updates in thoracic SMARCA4-deficient undifferentiated tumor","volume":"38","author":"Nambirajan","year":"2021","journal-title":"Semin Diagn Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1509537\/v1","article-title":"Clinical, radiological and pathological features of SMARCA4 \/ BRG1-deficient non-small cell lung carcinomas","author":"Lou","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107818","article-title":"Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods","volume":"192","author":"Shi","year":"2024","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103472","article-title":"SWI\/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication","volume":"9","author":"Pang","year":"2024","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100476","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor with ALK fusion treated with alectinib achieved remarkable tumor regression: Case report","volume":"4","author":"Sheng","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00732-4","article-title":"The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation","volume":"31","author":"Li","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad175","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectives","volume":"54","author":"Shinno","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.anndiagpath.2016.10.006","article-title":"SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens","volume":"26","author":"Herpel","year":"2017","journal-title":"Ann Diagn Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2019.10.009","article-title":"Non-small cell lung cancer with loss of expression of the SWI\/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden","volume":"138","author":"Naito","year":"2019","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100235","article-title":"Conversion surgery for advanced thoracic SMARCA4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: A case report","volume":"2","author":"Kunimasa","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3718","article-title":"Safety and efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz160","article-title":"Long lasting\u00a0major response to pembrolizumab in a thoracic Malignant rhabdoid-like SMARCA4-deficient tumor","volume":"30","author":"Henon","year":"2019","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1131448","article-title":"Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13070","article-title":"Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report","volume":"10","author":"Naito","year":"2019","journal-title":"Thorac Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-021-00472-4","article-title":"Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor","volume":"10","author":"Tanaka","year":"2021","journal-title":"Int Cancer Conf J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/imt-2020-0311","article-title":"Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma","volume":"13","author":"Kawachi","year":"2021","journal-title":"Immunotherapy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.170","article-title":"MA08.09 SMARCA4 deficient thoracic tumors: Clinicopathological, molecular characteristics and optimal therapeutics methods","volume":"18","author":"Pang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1530142","article-title":"Case report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer","volume":"15","author":"Pan","year":"2025","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1724204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:55:43Z","timestamp":1774421743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1724204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1724204"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1724204","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"1724204"}}